国产精品日韩欧美一区二区_久久夜色精品国产欧美乱_久久精品一区二区三区免费_亚洲日韩久久无码精彩_国产精品96久久久久久AV不卡_伊人久久精品无码AV一区二区三区

山東省眼科醫(yī)院史偉云院長(zhǎng)就世界首個(gè)SFDA批準(zhǔn)的生物工程角膜相關(guān)臨床問(wèn)題，接受了哥倫比亞電視臺(tái)的專訪。專訪以《Scientists?working?on?restoring?human?sight?with?pig?eyes》為題在哥倫比亞電視臺(tái)播出后，引起了極大反響。
? 史偉云院長(zhǎng)詳細(xì)介紹了世界首個(gè)SFDA批準(zhǔn)的生物工程角膜臨床應(yīng)用情況：“生物工程角膜是由異種角膜經(jīng)脫細(xì)胞特殊工藝的多級(jí)處理，去除了角膜中的細(xì)胞、雜蛋白、多糖等抗原，保留了天然角膜基質(zhì)膠原蛋白結(jié)構(gòu)及透明性，生物相容性好，生物安全性高，能與周圍組織快速整合，移植角膜透明，患者視力快速恢復(fù)。這是擁有完整自主知識(shí)產(chǎn)權(quán)的高科技劃時(shí)代產(chǎn)品?！?
? 同時(shí)史偉云院長(zhǎng)強(qiáng)調(diào)：“人工生物角膜與捐獻(xiàn)人角膜在移植手術(shù)技術(shù)上有著明顯的特點(diǎn)，不論從手術(shù)適應(yīng)癥選擇到圍手術(shù)期處理都有著獨(dú)特的技巧，因此生物工程角膜移植手術(shù)醫(yī)師培訓(xùn)是角膜盲患者復(fù)明的不可或缺的關(guān)鍵因素。”
在山東省眼科醫(yī)院工作人員的引導(dǎo)下，經(jīng)過(guò)消毒等程序，采訪組部分人員獲得允許進(jìn)入手術(shù)室對(duì)史偉云院長(zhǎng)使用組織工程角膜進(jìn)行角膜移植手術(shù)進(jìn)行拍攝，史偉云院長(zhǎng)精湛的手術(shù)技術(shù)讓從事多年醫(yī)療采訪的哥倫比亞電視臺(tái)記者十分驚訝，連連稱贊：“觀看史院長(zhǎng)做手術(shù)就像在欣賞一場(chǎng)精彩的演出。”
? 采訪期間，史偉云院長(zhǎng)詼諧的說(shuō)：“你們哥倫比亞電視臺(tái)因?yàn)榕_(tái)標(biāo)像眼睛，所以在美國(guó)也被稱作‘眼睛臺(tái)’，這跟我們眼科有很深的淵源啊?！笔吩洪L(zhǎng)的詼諧引讓采訪氣氛格外輕松。
? 哥倫比亞電視臺(tái)記者還對(duì)已經(jīng)接受過(guò)生物工程角膜移植的患者進(jìn)行了采訪。

? 相關(guān)資料：
? 以山東省眼科研究所、山東省眼科醫(yī)院謝立信院士和泰山攀登計(jì)劃特聘專家史偉云教授帶領(lǐng)的學(xué)術(shù)團(tuán)隊(duì)是中國(guó)再生醫(yī)學(xué)國(guó)際公司研發(fā)的全球首個(gè)生物工程角膜技術(shù)支持的主要力量。該生物角膜于2015年4月底獲得國(guó)家食品藥品監(jiān)督管理總局頒發(fā)的醫(yī)療器械注冊(cè)證書(shū)，2015年5月23日正式投產(chǎn)上市。作為全球首個(gè)生物工程角膜，可廣泛應(yīng)用于50%的角膜盲治療，將極大地緩解我國(guó)捐獻(xiàn)角膜奇缺的臨床困境，為我國(guó)400萬(wàn)乃至全球6000萬(wàn)的角膜盲患者帶來(lái)復(fù)明的希望。2015年9月上市后的世界首例生物工程角膜臨床移植在山東省眼科研究所（青島眼科醫(yī)院，山東省眼科醫(yī)院）獲得成功。??
? 鑒于山東省眼科研究所在角膜研發(fā)中的巨大貢獻(xiàn)和在全國(guó)角膜病基礎(chǔ)與臨床研究領(lǐng)域的龍頭地位，首個(gè)生物工程角膜手術(shù)醫(yī)生培訓(xùn)基地已在山東省眼科醫(yī)院建立。2016年7月至今已培訓(xùn)近300名國(guó)內(nèi)學(xué)員，十余位國(guó)際學(xué)員，培訓(xùn)班使學(xué)員們對(duì)生物工程角膜有了更加深刻的認(rèn)識(shí)，同時(shí)提高了臨床實(shí)踐能力與手術(shù)技能，為更好從事角膜病防治工作奠定了理論與實(shí)踐基礎(chǔ)。

史偉云教授簡(jiǎn)介：

眼科學(xué)博士，二級(jí)教授、主任醫(yī)師，博士生導(dǎo)師。中華醫(yī)學(xué)會(huì)眼科學(xué)分會(huì)常委、專家會(huì)員，中華醫(yī)學(xué)會(huì)眼科學(xué)分會(huì)角膜病組組長(zhǎng)，《中華眼科雜志》副總編輯及其他8個(gè)眼科雜志編委?，F(xiàn)任山東省眼科研究所黨委書(shū)記、所長(zhǎng)、山東省眼科醫(yī)院院長(zhǎng)。國(guó)務(wù)院特殊津貼專家、山東省泰山崗位攀登計(jì)劃特聘專家、省有突出貢獻(xiàn)的中青年專家和山東省首屆醫(yī)學(xué)領(lǐng)軍人才。在臨床工作方面，具有豐富的臨床經(jīng)驗(yàn)和嫻熟的顯微手術(shù)技巧，能熟練完成各類眼前段手術(shù)，如抗青光眼、白內(nèi)障超聲乳化摘除聯(lián)合人工晶體植入和各種眼科屈光手術(shù)等，尤其在角膜移植術(shù)手術(shù)方面具有較高的造詣，能夠熟練進(jìn)行各類復(fù)雜的角膜移植術(shù)，已累計(jì)完成近萬(wàn)例?？蒲薪虒W(xué)方面，作為課題負(fù)責(zé)人或主要人員共承擔(dān)科研課題?20?余項(xiàng)，獲得國(guó)家發(fā)明專利?4?項(xiàng)。其中作為負(fù)責(zé)人承擔(dān)國(guó)家?863?重大課題、973?重大專項(xiàng)、國(guó)家自然科學(xué)基金重點(diǎn)項(xiàng)目和面上項(xiàng)目、山東省自然科學(xué)基金及省攻關(guān)課題等。發(fā)表論文?258?篇、其中?SCI?收錄?53?篇，第一和通訊作者在（PNAS、Ophthalmology）等?SCI?收錄31篇，人民衛(wèi)生出版社出版我國(guó)首部《角膜手術(shù)學(xué)》和《角膜病學(xué)》學(xué)術(shù)專著，獲國(guó)家科技進(jìn)步二等獎(jiǎng)兩項(xiàng)和為首獲山東省科技進(jìn)步一等獎(jiǎng)兩項(xiàng)。
? 哥倫比亞電視臺(tái)簡(jiǎn)介：

美國(guó)哥倫比亞電視臺(tái)，是美國(guó)五大電視臺(tái)之一，是具有巨大世界影響力的的國(guó)際化電視臺(tái)。縮寫(xiě)為CBS，美國(guó)三大全國(guó)性商業(yè)廣播電視網(wǎng)之一。1927年成立?？偛吭O(shè)在紐約。1941年，正式開(kāi)辦電視廣播，1954年，播出彩色電視。1987年在紐約等城市直接經(jīng)營(yíng)電視臺(tái)5座，中波廣播電臺(tái)6座，調(diào)頻廣播電臺(tái)7座。另有通過(guò)合同關(guān)系參加該廣播網(wǎng)的電視臺(tái)?200多座，形成全國(guó)性廣播電視網(wǎng)。

史偉云院長(zhǎng)向哥倫比亞電視臺(tái)記者介紹生物工程角膜相關(guān)情況

?

史偉云院長(zhǎng)精湛的手術(shù)技術(shù)讓從事多年醫(yī)療采訪的哥倫比亞電視臺(tái)記者十分驚訝

?

哥倫比亞電視臺(tái)記者對(duì)已經(jīng)接受過(guò)生物工程角膜移植的患者進(jìn)行采訪

?

史偉云院長(zhǎng)、高華副院長(zhǎng)與哥倫比亞電視臺(tái)專訪攝制組合影

President Weiyun SHI of Shandong Eye Hospital Accepted an Exclusive Interview with Columbia Broadcasting System

President Weiyun SHI of Shandong Eye Hospital accepted an exclusive interview with Columbia Broadcasting System on the clinical questions about the world’s first bio-engineered cornea approved by SFDA. The broadcasting of the interview named “Scientists working on restoring human sight with pig eyes” on CBS has drawn a great deal of public attention.

President SHI gave a detailed introduction to the clinical application condition of the world’s first bio-engineered cornea approved by SFDA: “The bioengineered corneas are made from xenogeneic corneas through multilevel processing using decellularized special techniques, which remove antigens in corneas like cells, impure protein and polysaccharide and preserve the structure of natural corneal stromal collagens and their transparency. The biocompatibility is good and the biosecurity is high. They can integrate into the surrounding tissue quickly. With transparent transplanted cornea, the visual acuity of patients can be improved quickly. This is an epoch-making high-tech production with complete independent intellectual property rights.”

At the same time, president SHI stressed: “The characteristics of surgical techniques for transplanting artificial biological cornea and donor cornea are obvious. Both the selection of surgical indications and the treatment during perioperative period need unique techniques, so training surgeons for bio-engineered corneal transplantation is an indispensable step in the way to restore sight for patients with corneal blindness.”

Under the guidance of the staff of Shandong Eye Hospital, several members of the interviewing group were allowed to enter the operating room after the disinfection and other procedures to shoot the cornea transplant surgery with tissue engineering cornea by president SHI. The excellent surgical techniques amazed the CBS reporter, who had conduced medical interviews for many years. “Watching the surgery by president SHI is just like watching a wonderful performance.” She praised again and again.

During the interview, president SHI said humorously: “Sometimes CSB is referred to as ‘Eye Network’ as your logo looks like an eye. You see, CBS and ophthalmology are closely connected.” These words made the interview atmosphere more relaxing.

The CBS reporter also interviewed a patient who had received bio-engineered corneal transplantation.

?

Relative information：

The academic team led by Academician Lixin XIE and Professor Weiyun SHI of Shandong Eye Institute and Shandong Eye Hospital is the main technical support power for the world’s first bio-engineered cornea developed by China Regenerative Medicine International Limited. The bio-engineered cornea has obtained the Registration Certificate for Medical Device from CFDA at the end of April, 2015 and was officially put into production and market on May, 23, 2015. As the world's first bio-engineered cornea, it can be widely used in 50% of corneal blind treatment, which can greatly alleviate the clinical situation of low cornea donation rate in China, and bring hope of regaining sight for 4 million corneal blind patients in China and even 60 million all over the world. The world's first bioengineered corneal clinical transplantation conducted at Shandong Eye Institute (Qingdao Eye Institute, Shandong Eye Hospital) in September 2015 was successful.

In view of the great contributions Shandong Eye Institute has made in the research and development of cornea and its leading role in the basic and clinical researches of corneal disease in China, the first doctor training base for bio-engineered corneal transplantation was established at Shandong Eye Hospital. Since July 2016, nearly 300 domestic doctors and over 10 international doctors have been trained here. The training has helped the doctors to establish a deeper understanding towards bio-engineered cornea and has improved doctors’ clinical practical ability and surgical techniques.